Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to estimate the maximum tolerated dose of dexamethasone given
for 5 consecutive days when combined with fixed doses of irinotecan (given IV, qd x 5, 2 days
off, qd x 5) and vincristine (given IV, 2 doses total on days 1 and 8 of schedule) in
children with relapsed or refractory hematologic malignancies. In addition we will also study
the pharmacokinetics of irinotecan when given without and then with dexamethasone in each
patient, evaluate the relationship between irinotecan pharmacokinetic parameters and toxicity
and describe any antitumor effects.